impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

 

  1. Division of Rheumatology, Consorci Sanitari de Terrassa, Barcelona, Spain.
  2. Research Unit of Spanish Society of Rheumatology, Madrid, Spain.
  3. Division of Rheumatology, Hospital U. de Elda, Alicante, Spain.
  4. Division of Rheumatology, Hospital U. de la Princesa, IIS-IP, Madrid, Spain.
  5. Division of Cardiology, Hospital U. Lucus Augusti, Lugo, Spain.
  6. Research Unit of Spanish Society of Rheumatology, Madrid, Spain.
  7. Division of Rheumatology, Hospital Universitari Dexeus, Barcelona, Spain.
  8. Division of Rheumatology, Hospital Clínic i Provincial, Barcelona, Spain.
  9. Division of Rheumatology, Hospital U. de la Princesa, IIS-IP, Madrid, Spain.
  10. Division of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain.
  11. Division of Rheumatology, Ponferrada, León, Spain.
  12. Division of Rheumatology, Hospital Miguel Servet, Zaragoza, Spain.
  13. Division of Rheumatology, Hospital Marina Baixa, La Vila Joiosa, Alicante, Spain.
  14. Division of Rheumatology, Hospital General U. de Valencia, Spain.
  15. Division of Rheumatology, Hospital de Viladecans, Barcelona, Spain.
  16. Division of Rheumatology, Hospital de Barbastro, Huesca, Spain.
  17. Division of Rheumatology, Hospital de Sant Rafael, Barcelona, Spain.
  18. Division of Rheumatology, Instituto Poal, Barcelona, Spain.
  19. University of Cantabria, IDIVAL, Santander, Spain, and CIBER Epidemiologia y Salud Pública (CIBERESP), Spain.
  20. Epidemiology, Genetics & Atherosclerosis Res. Group on Systemic Inflammatory Diseases, Rheumatology Div., Hosp. Univ. Marqués de Valdecilla, IDIVAL, Univ. of Cantabria, Santander, Spain, and Univ. of the Witwatersrand, Johannesburg, South Africa.

on behalf of the CARMA Project Collaborative Group

CER11721
2019 Vol.37, N°5
PI 0774, PF 0782
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 30789151 [PubMed]

Received: 09/09/2018
Accepted : 19/11/2018
In Press: 15/02/2019
Published: 29/08/2019

Abstract

OBJECTIVES:
Cardiovascular (CV) disease is one of the main causes of morbi-mortality in spondyloarthritis (SpA), partially explained by traditional CV risk factors. Information on lipoprotein(a) [Lp(a)], a non-conventional risk factor, in SpA is scarce. In this study we assessed the prevalence of hyperlipoproteinaemia(a) in SpA patients and analysed the possible related factors.
METHODS:
A baseline analysis was made of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients and controls included in the CARMA project (CARdiovascular in RheuMAtology), a 10-year prospective study evaluating the risk of CV events in chronic inflammatory rheumatic diseases. A multivariate logistic regression model was performed using hyperlipoproteinaemia(a) (Lp(a) >50 mg/dl) as a dependent variable and adjusting for confounding factors.
RESULTS:
19.2% (95% CI: 16.80-22.05) of the SpA patients [20.7% (95% CI: 16.91-24.82) of those with AS and 17.7% (95% CI: 14.15-21.75) of those with PsA] and 16.7% (95% CI: 13.23-20.86) of the controls had hyperlipoproteinaemia(a) (p=0.326). Adjusting for age and sex, SpA patients were more likely to have hyperlipoproteinaemia(a) than controls (OR: 1.43, 95%CI: 1.00-2.04; p=0.05), especially those with AS (OR: 1.81, 95%CI: 1.18-2.77; p=0.007). In the adjusted model, apolipoprotein B in all patients, non-steroidal anti-inflammatory drugs in AS, and female sex in PsA, were associated with hyperlipoproteinaemia(a). No disease-specific factors associated with hyperlipoproteinaemia(a) were identified.
CONCLUSIONS:
SpA patients show a moderately increased risk of hyperlipoproteinaemia(a) compared to controls, especially those with AS. Lp(a) determination may be of interest to improve the CV risk assessment in SpA patients.

Rheumatology Article